Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures

Next Previous
X
Search
Trial Profile

Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 11 Feb 2020 According to a m8 Pharmaceuticals media release, the moksha8 Pharmaceuticals has changed its m8 Pharmaceuticals.
    • 15 Jul 2014 According to a Bial media release, eslicarbazepine acetate was approved in Europe on the basis of efficacy and safety data from this and four other phase III trials (see profiles 70037569, 70037570, 70037571 and 70049692.)
    • 05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top